13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001825034
Total reported value
$439.8M
$439.8M
12 檔
202.1%
According to the latest 13F quarterly dataset, Euclidean Capital LLC managed an equity portfolio of $439.8M at the end of Q3 2024, spanning 12 distinct U.S. exchange-listed positions.
In Q3 2024, Euclidean Capital LLC displayed an active expansion posture, initiating 1 new positions and adding to 1 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 76.11% | — | +4.87% | |
| 2 | INDA | Ishares Msci India ETF | ETF-Other | 15.65% | -0.26% | — | |
| 3 | VEU | Vanguard Ftse All-world Ex-u | ETF-Other | 3.53% | -0.33% | — | |
| 4 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 1.62% | -0.17% | — | |
| 5 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.12% | -0.76% | — | |
| 6 | ALEC | Alector Inc | Stock-Other | 0.67% | -0.12% | — | |
| 7 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 0.43% | -0.03% | — | |
| 8 | ✓ | Stock-Other | 0.40% | — | — | ||
| 9 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.22% | -0.01% | — | |
| 10 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.15% | — | — | |
| 11 | SRZN | Surrozen Inc | Stock-Other | 0.12% | -0.13% | — | |
| 12 | SRZNW | Surrozen Inc-cw25 | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VEU | Vanguard Ftse All-world Ex-u | +3.5% | NEW | New buy |
| 2 | FHTX | Foghorn Therapeutics Inc | +0.5% | — | Unchanged |
| 3 | ORIC | Oric Pharmaceuticals Inc | +0.2% | — | Unchanged |
| 4 | SRZN | Surrozen Inc | — | — | Unchanged |
| 5 | SRZNW | Surrozen Inc-cw25 | — | — | Unchanged |
| 6 | ALEC | Alector Inc | -0.1% | — | Unchanged |
| 7 | ✓ | Rapt Therapeutics Inc | -0.1% | — | Unchanged |
| 8 | ✓ | -0.1% | — | Unchanged | |
| 9 | PMVP | Pmv Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 10 | TNYA | Tenaya Therapeutics Inc | -0.2% | — | Unchanged |
| 11 | INDA | Ishares Msci India ETF | -1.4% | — | Unchanged |
| 12 | SPY | Ss Spdr S&p 500 ETF Trust-us | -2.3% | +4.87% | Add |
According to official SEC Form 13F filings, Euclidean Capital LLC reported a total U.S. public equity portfolio value of $439.8M across 12 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SPY, INDA, VEU) accounted for 202.1% of total reported equity market value during Q3 2024.
Top New Position Initiated
VEU
市值: $32.0M
During Q3 2024, Euclidean Capital LLC's top holdings by market value included SPY (76.1%)、INDA (15.7%)、VEU (3.5%). The largest single position, SPY, represented 76.1% of total portfolio value.
In Q3 2024, Euclidean Capital LLC made 2 total portfolio adjustments, initiating 1 new buys, adding to 1 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.